Your browser doesn't support javascript.
Therapeutic Polypeptides and Peptidomimetics: Powerful Tools for COVID-19 Treatment.
Liu, Xinyu; Shi, Jian; Wang, Deyang; Su, Ying; Xing, Zhen; Sun, Fei; Chen, Fei.
  • Liu X; Department of Physiology, Jining Medical University, 133 Hehua Rd, Jining, 272067, China.
  • Shi J; Department of Physiology, Jining Medical University, 133 Hehua Rd, Jining, 272067, China.
  • Wang D; Department of Physiology, Jining Medical University, 133 Hehua Rd, Jining, 272067, China.
  • Su Y; Dongping County People's Hospital, Tai-an, China.
  • Xing Z; Dongping County People's Hospital, Tai-an, China.
  • Sun F; Qilu Medical University, Zibo, China.
  • Chen F; Department of Physiology, Jining Medical University, 133 Hehua Rd, Jining, 272067, China. chenfei0336@163.com.
Clin Drug Investig ; 2022 Dec 03.
Article in English | MEDLINE | ID: covidwho-2242804
ABSTRACT
The coronavirus disease 2019 (COVID-19) pandemic has swept the whole world and brought about a public health crisis of unprecedented proportions. To combat the rapid transmission and possible deaths due to the disease, researchers and companies around the world are developing all possible strategies. Due to the advantages of safety, specificity, and fewer adverse effects, polypeptide and peptidomimetic drugs are considered promising strategies. This review comprehensively summarizes and discusses the progress in development of peptide drugs for use in the treatment of COVID-19. Based on the latest results in this field, we divided them into clinically approved drugs, clinical trial drugs, and clinically ineffective drugs, and outlined the molecular targets and mechanisms of action one by one to reveal their feasibility as promising therapeutic agents for COVID-19. Notably, monoclonal antibodies have shown beneficial effects in the early stages of infection, while Paxlovid can significantly reduce hospitalization and mortality among non-vaccinated patients. Among clinical experimental drugs, both the interleukin-1 receptor antagonist anakinra and the bradykinin B2 receptor antagonist icatibant are well tolerated and effective in patients with COVID-19, but long-term trials are needed to confirm the durability of efficacy.

Full text: Available Collection: International databases Database: MEDLINE Type of study: Prognostic study / Randomized controlled trials Topics: Vaccines Language: English Journal subject: Pharmacology / Drug Therapy Year: 2022 Document Type: Article Affiliation country: S40261-022-01231-w

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Prognostic study / Randomized controlled trials Topics: Vaccines Language: English Journal subject: Pharmacology / Drug Therapy Year: 2022 Document Type: Article Affiliation country: S40261-022-01231-w